Table 4 Association between lymph node metastasis and preoperative clinical risk factors according to the biopsy histological grade.

From: Predictive model for the preoperative assessment and prognostic modeling of lymph node metastasis in endometrial cancer

Category

LGEC

HGEC

Univariate

Multivariate

Univariate

Multivariate

OR

(95%CI)

P value

OR

(95%CI)

P value

OR

(95%CI)

P value

OR

(95%CI)

P value

(A) NCCH cohort (n = 125, [LGEC: n = 71, HGEC: n = 54])

MRI

 Myometrial invasion (≥ 50% / < 50%)

2.81

(1.01–7.80)

0.047

1.79*

(0.50–6.44)

0.38

9.95

(2.85–34.8)

 < 0.01

9.52*

(2.37–38.2)

 < 0.01

 Tumor diameter (high / low)1

6.01

(2.06–17.6)

 < 0.01

2.18*

(0.58–8.28)

0.25

2.52

(0.84–7.58)

0.10

–

–

–

 Enlarged lymph nodes (positive / negative)

10.3

(2.52–41.9)

 < 0.01

9.26*

(1.73–49.5)

 < 0.01

2.43

(0.62–9.56)

0.20

–

–

–

 Serum CA125 level (high / low)2

8.74

(2.87–26.6)

 < 0.01

7.72*

(2.04–29.2)

 < 0.01

18.7

(2.18–160.1)

 < 0.01

17.5*

(1.72–178.2)

0.016

(B) SUH cohort (n = 129, [LGEC: n = 94, HGEC: n = 35])

MRI

 Myometrial invasion (≥ 50% / < 50%)

3.12

(1.14–8.52)

0.026

1.99*

(0.62–6.31)

0.24

8.57

(1.39–52.7)

0.021

4.86*

(0.63–37.5)

0.13

Tumor diameter (high / low)1

2.61

(0.96–7.09)

0.060

–

–

–

2.43

(0.48–12.3)

0.29

–

–

–

 Enlarged lymph nodes (positive / negative)

1.82

(0.31–10.7)

0.51

–

–

–

15.6

(1.34–182.1)

0.028

3.43*

(0.14–82.8)

0.45

 Serum CA125 level (high / low)2

15.1

(4.46–51.4)

 < 0.01

13.2*

(3.83–45.7)

 < 0.01

13.3

(2.06–86.3)

 < 0.01

4.38*

(0.37–52.1)

0.24

(C) Combined NCCH cohort and SUH cohort (n = 254)

MRI

 Myometrial invasion (≥ 50% / < 50%)

3.14

(1.55–6.38)

 < 0.01

1.97**

(0.84–4.63)

0.12

9.37

(3.45–25.5)

 < 0.01

7.86**

(2.49–24.8)

 < 0.01

 Tumor diameter (high / low)1

3.86

(1.88–7.93)

 < 0.01

1.98**

(0.83–4.70)

0.12

2.51

(1.03–6.09)

0.042

1.18**

(0.36–3.88)

0.79

 Enlarged lymph nodes (positive / negative)

6.06

(2.24–16.4)

 < 0.01

6.20**

(1.71–22.5)

 < 0.01

4.43

(1.36–14.4)

0.013

2.14**

(0.45–10.2)

0.34

Serum CA125 level (high / low)2

10.2

(4.69–22.4)

 < 0.01

10.1**

(4.11–25.0)

 < 0.01

10.8

(3.18–36.9)

 < 0.01

7.32**

(1.40–38.3)

0.019

  1. LGEC Low-grade endometrial cancer, HGEC High-grade endometrial cancer, OR Odds ratio, CI Confidence interval, NCCH National Cancer Center Hospital, MRI Magnetic resonance imaging, CA125 Cancer antigen 125, SUH Showa University Hospital.
  2. *Adjusted by statistically significant variables in univariate analysis. **Adjusted by cohort and statistically significant variables in univariate analysis.
  3. 1High level, > 47 mm. 2High level, > 52.3U/mL(unmenopause), > 48U/mL(menopause).
Back to article page